Results 1 to 10 of about 19,435 (124)
New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics [PDF]
PathogensThe growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou +4 more
doaj +2 more sources
Revisiting the Checkerboard to Inform Development of β-Lactam/β-Lactamase Inhibitor Combinations [PDF]
AntibioticsA two-dimensional “checkerboard” array employing systematic titration (e.g., serial two-fold dilutions) is a well-established in vitro method for exploring the antibacterial effects of novel drug combinations.
Darren J. Bentley
doaj +2 more sources
β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development [PDF]
PathogensAntimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou +4 more
doaj +2 more sources
EngineeringThis work explores the potential of a triple combination of meropenem (MEM), a novel metallo-β-lactamase (MBL) inhibitor (indole-2-carboxylate 58 (InC58)), and a serine-β-lactamase (SBL) inhibitor (avibactam (AVI)) for broad-spectrum activity against ...
Jürgen Brem +2 more
exaly +3 more sources
Clinical and Research Journal in Internal Medicine, 2021 Background: β-lactamase is an enzyme that plays a role in the occurrence of antibiotic resistance against Methicillin-resistant Staphylococcus aureus (MRSA) bacteria. Viscosin is a lipopeptide biosurfactant produced by the Pseudomonas group bacteria.
Mokhamad Fahmi Rizki Syaban +4 more
openaire +1 more source
Frontiers in Cellular and Infection Microbiology, 2022 ObjectivesThe addition of novel β-lactamase inhibitors to carbapenems restores the activity against multidrug-resistant Gram-negative bacteria. The aim of this study was to summarize the evidence on the efficacy and safety of novel carbapenem–β-lactamase
Wei Yu +4 more
doaj +1 more source
Penetration of β-lactamase inhibitors into the periplasm of Gram-negative bacteria [PDF]
FEMS Microbiology Letters, 1999 The effectiveness of a beta-lactamase inhibitor/beta-lactam combination against Gram-negative pathogens depends on many interplaying factors, one of which is the penetration of the inhibitor across the outer membrane. In this work we have measured the relative penetrations of clavulanic acid, sulbactam, tazobactam and BRL 42715 into two strains of ...
Farmer TH, Degnan BA, Payne DJ
openaire +3 more sources
Outer membrane permeability of β-lactamase inhibitors inPseudomonas aeruginosa [PDF]
FEMS Microbiology Letters, 1995 Evaluation of four beta-lactamase inhibitors in terms of their outer membrane permeability in Pseudomonas aeruginosa revealed that sulbactam and tazobactam diffused most efficiently and equally well. That of BRL42715 appeared to be a factor of ten lower than that of the above two, but it showed the strongest beta-lactamase inhibitory activity.
S, Satake, T, Nakae
openaire +2 more sources
Comparative Evaluation of the in-vitro Activity of Six β-lactam/β-lactamase Inhibitor Combinations against Gram Negative Bacilli [PDF]
Journal of Clinical and Diagnostic Research, 2013 Background: The extensive use of the β-lactam antibiotics in hospitals and in the community has created major resistance problems which has led to increased morbidity, mortality and healthcare costs.
Smita Sood
doaj +1 more source
Iranian Journal of Microbiology, 2022 Background and Objectives: Escherichia coli (E. coli) is an important member of Enterobacteriaceae family involved in severe infections. The increased rate of resistance towards different classes of antibiotics limits their treatment options. The aim of
Ashraf Ahmed Kadry +2 more
doaj +1 more source